Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in Multiple System Atrophy
2021-003231-29Phase 2Completed
- Sponsor
- Alterity Therapeutics
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple system atrophy (MSA) comparing ATH434 with Placebo (2 arms). Primary endpoint: Change in brain iron content by MRI. Started Jan 2022; status: completed.
02
Drugs
ATH-434
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on 2021-003231-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003231-29.